摘要:
Novel polypeptides having fibrinogenolytic properties and having amino acid sequences as SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 indicated in the Sequence Listing, the preparation and use thereof for controlling diseases.
摘要翻译:具有纤维蛋白原分解性质并具有序列表中所示的SEQ ID NO:3,SEQ ID NO:4,SEQ ID NO:5和SEQ ID NO:6的氨基酸序列的新型多肽,其控制疾病的制备和用途。
摘要:
The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Aβ(20-42) globulomer or any Aβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided.
摘要:
The invention relates to neuromodulatory oligomers of the amyloid-β(1-42) protein, a particular production method, by means of which the oligomer can be obtained in a reproducible manner at high yield, the use of the oligomers as diagnostic and therapeutics agents, for the generation of oligomer-specific antibodies and for the discovery of substances which can interact with the oligomers and in the formation thereof. Corresponding methods for the production of the antibodies and for discovery of the substances are also disclosed as are the antibodies themselves and the use of the antibodies or substances as diagnostic and therapeutic agents. The invention further relates to derivatives of the oligomers and oligomers based on abbreviated forms of the amyloid-β(1-42) proteins, the production and use thereof.
摘要:
The present invention relates to carboxylic acid derivatives of the formula I the substituents having the meanings explained in the description, preparation and use as endothelin receptor antagonists.
摘要:
Novel proteins which have a molecular weight of about 42,000 daltons and have at the N terminus the amino acid sequenceXaa Thr Pro Tyr Ala Pro Glu Pro Gly Set Thr Cys Arg Leu Arg Gluwhere X is hydrogen, a phenylalanine residue (Phe) or the amino acid sequences Ala Phe, Val Ala Phe, Gln Val Ala Phe, Ala Gln Val Ala Phe, Pro Ala Gln Val Ala Phe or Leu Pro Ala Gln Val Ala Phe, and which are suitable for the treatment of diseases, are described.
摘要翻译:PCT No.PCT / EP90 / 00719 Sec。 371日期1991年9月26日 102(e)1991年9月26日PCT PCT 1990年5月4日PCT公布。 第WO90 / 13575号公报 日期:1990年11月15日。分子量为约42,000道尔顿且在N末端具有氨基酸序列的新型蛋白质Xaa Thr Pro Tyr Ala Pro Glu Pro Gly Set Thr Cys Arg Leu Arg Glu,其中X为氢, 苯丙氨酸残基(Phe)或氨基酸序列Ala Phe,Val Ala Phe,Gln Val Ala Phe,Ala Gln Val Ala Phe,Pro Ala Gln Val Ala Phe或Leu Pro Ala Gln Val Ala Phe,适用于治疗 的疾病。
摘要:
The subject invention relates to monoclonal antibodies (e.g., 8F5 and 8C5) that may be used, for example, in the prevention, treatment and diagnosis of Alzheimer's Disease or other neurodegenerative disorders.
摘要:
The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.
摘要:
The subject invention relates to the cloning, expression and isolation of recombinant forms of beta-amyloid protein containing a N-terminal methionine (or one or more amino acids) as well as to methods of using this recombinant protein in the production of therapeutic antibodies, in the identification of therapeutic small molecules, and in the performance of diagnostic assays.
摘要:
The subject invention relates to monoclonal antibodies that may be used in the treatment and diagnosis of Alzheimer's Disease. In particular, the present invention relates to monoclonal antibodies referred to as 10F4 and 3C5 and to other monoclonal antibodies (e.g., murine, human or humanized) having similar properties thereto.